KDR and medullary thyroid gland carcinoma: Vandetanib (Caprelsa, ZD6474) is a multitarget inhibitor of tyrosine kinase receptors EGFR, vascular endothelial growth factor receptor-2 (VEGFR-2), and RET [150] that was approved by the FDA as a treatment against advanced medullary thyroid cancer [151].